Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 19.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Eisai Inc., Genentech, Genomic Health, Inc., Lilly, Merck & Co., Inc., Nektar Therapeutics, Novartis Pharmaceuticals Corporation, and Puma Biotechnology, Inc.
The 14th AnnualInternational Congress on the Future of Breast Cancer® serves as an update on advances in the breast cancer field, with a focus on the clinical implications of breast cancer genetic and phenotypic subtyping. Novel agents, strategies, and improved regimens are changing the future of breast cancer therapy, and these advances and their clinical impact are highlighted throughout the program. Current controversies in the field are also addressed and debated and new data presented, along with information about how to optimally individualize breast cancer therapy. This conference provides a unique opportunity for medical, surgical, and radiation oncologists and other health care professionals to learn from and interact with international leaders in breast cancer in order to increase knowledge, apply new data to practice, and ultimately improve patient outcomes.
Adjuvant endocrine therapy -- how to optimize duration and address adherence?
What’s new in (neo)adjuvant therapy for HER2+ and triple-negative breast cancers?
How does obesity impact early-stage breast cancer treatment strategies?
Emerging immunotherapies for breast cancer -- hype or hope?
Do novel genomic and proteomic diagnostic assays have utility in the clinic today?
How can novel germline mutations be used for identifying and managing hereditary breast cancer risk?
What new strategies are on the horizon for reducing breast cancer development and recurrence?
How are locoregional treatment strategies evolving? What management challenges and controversies remain?
Where to next? Promising novel agents and subtype-specific treatment paradigms for metastatic disease, including ER+, HER2+, and triple-negative breast cancers
What are the implications of health care reform for oncology practice?
This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer may also participate.
At the conclusion of this activity, participants should be better prepared to:
Incorporate current guidelines and recent data on local therapies, including advances in surgical and radiation therapy, into the treatment of patients with breast cancer
Integrate biomarkers, molecular assays, and other risk assessment tools in treatment decision making for breast cancer, when appropriate
Personalize treatment utilizing targeted therapies where appropriate, based on predictive and prognostic molecular markers through multiple lines of therapy
Review current standards and emerging data regarding systemic therapies for the treatment of early-stage, locally advanced, and metastatic breast cancer
Incorporate systemic therapies for breast cancer (including endocrine, cytotoxic, targeted, and bone-modifying agents) into individualized treatment plans for patients based upon an evaluation of efficacy and safety, as well as patient and tumor characteristics
Identify appropriate clinical trials designed to benefit patients with breast cancer
Joyce A. O'Shaughnessy, MD
Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
The US Oncology Network
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.
Faculty and Staff Disclosures
The following individuals have no relevant financial relationships with commercial interests to disclose:Linda Bosserman, MD; AneesChagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C); Frankie Ann Holmes, MD, FACP; Fred Kass, MD; Michael Lewis, PhD; Rita Nanda, MD; Debra Patt, MD, MPH, MBA; Melvin Silverstein, MD, FACS; Frank Vicini, MD, FACR; Jeffrey Weitzel, MD
The staff of PER®: Ann C. Lichti, CHCP; Susan Peck, PhD; Michael Perlmutter, PharmD, MS
The following individuals have relevant financial relationships with commercial interests to disclose:
Kathy Albain, MD, FACP, FASCO Consultant: Genomic Health; Rowan Chlebowski, MD, PhD Research Support: National Institutes of Health; Consultant: Novartis, Genentech, Amgen, Genomic Health, Pfizer, Novo Nordisk; Speakers Bureau: Novartis, Genentech; Anthony Elias, MD Research Support: Clinical trial support from multiple companies including Medivation and Astellas Pharma; Consultant: Genentech; Mohammad Jahanzeb, MD, FACP Research Support: Lilly, AbbVie, Genentech, Novartis; Consultant: Novartis; Eleftherios Mamounas, MD, MPH, FACS Consultant: Genomic Health, Celgene, Pfizer; Speakers Bureau: Genomic Health, Genentech/Roche; Ingrid Mayer, MD, MSCI Research Support: Novartis, Clovis Oncology; Advisory Board Member: Novartis; Gordon Mills, MD, PhD Research Support: Adelson Medical Research Foundation, AstraZeneca, Critical Outcome Technologies, GlaxoSmithKline, Illumina; Consultant: AstraZeneca, Blend Therapeutics, Critical Outcome Technologies, HanAl Bio Korea, Nuevolution, Novartis, Pfizer, Provista Diagnostics, Roche, SignalChem Lifesciences, Symphogen, Tau; Shareholder: Catena Pharmaceuticals, PTV Ventures, Spindletop Ventures; Pamela Munster, MD - Research Support: Merck, Novartis, Biomarin, Merrimack Pharmaceuticals, Calithera, Celgene; Consultant: Huya Bioscience International; Joyce O'Shaughnessy, MD Consultant: Arno Therapeutics, AstraZeneca, Celgene, Corcept Therapeutics, Eisai, Genentech, GlaxoSmithKline, Lilly, J&J, Merrimack, Novartis, Pfizer, Roche, Sanofi, Takeda Pharmaceutical, MedFusion; Lori Pierce, MD, FASTRO Shareholder: PFS Genomics (Founder’s Shares); Royalties: UpToDate; Lajos Pusztai, MD, DPhil Research Support: Merck, Genentech, Seattle Genetics, Foundation Medicine; Consultant: Pfizer, Celgene, BioTheranostics. Merck; Hope Rugo, MD, FACS Research Support: GlaxoSmithKline, Genentech/Roche, Merck, Novartis, Plexxikon, Eisai, OBI, Amgen, Pfizer, Macrogenics, Lilly; Speakers Bureau: Genomic Health; Joseph Sparano, MD Consultant: AstraZeneca, Novartis, Celgene, Genentech/Roche, Eli Lilly, Celldex Therapeutics; Shareholder: MetaStat;Sara Tolaney, MD, MPH Research Support: Genentech; Consultant: Lilly, Pfizer, Genentech; Douglas Yee, MD Research Support: I-SPY2 Trial Grant
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
Physician Payments Sunshine Act
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
You must be logged in to PER to register for this meeting